4/22/26

Dave Ricks, CEO of Eli Lilly: How a 150 Year Old Company Keeps Winning

Dave Ricks, Chair & CEO of Eli Lilly, joins inSpired to share how a 150 year old company became the most valuable healthcare company in the world. Nearly 10 years into his tenure as only the 12th CEO in Lilly’s history, Ricks explains how Lilly cut its drug development time to roughly six years, built a leading obesity franchise with Zepbound and Mounjaro, and is preparing for a market that could reach 100 million patients.

In this episode:

  • What has kept Lilly thriving for 150 years: science, long tenured people, and long term leadership

  • How big the obesity market can get, and why Lilly treats it more like a consumer market

  • The next wave of obesity medicines: retatrutide, orforglipron, and eloralintide

  • Why Lilly is betting on oral and once monthly options, and what makes a dosing schedule actually work

  • How obesity medicines may reshape immunology, brain health, and even cancer prevention

  • Lilly Direct, which now accounts for about a third of all obesity treatment in the United States

  • Why Ricks believes innovation will keep prices stable, and the fight against compounded copies

  • Lilly’s next frontiers in neuroscience and Alzheimer’s prevention, and a more open approach to M&A

  • The personal story that made the mission real for Ricks, and his goals for Lilly’s next decade

“I like to win a lot. And I don’t find a lot of satisfaction in coming in second.”

“If it says Lilly on it, we’re good.”

Chapters

  • Cold open

  • Thriving for 150 years

  • How big is the obesity market?

  • Is 100 million patients possible?

  • Next generation weight loss therapies

  • Retatrutide

  • Orforglipron and eloralintide

  • Brain health, immunology, and cancer

  • Lilly Direct

  • Price stability through innovation

  • Innovators vs. compounders

  • Neuroscience

  • M&A: opening the aperture

  • What inspires Dave Ricks

  • Navigating a complex healthcare landscape

  • Lilly’s goals for the next decade

Read the full transcript: Download the PDF

inSpired is for investors, by an investor: conversations with executives building tomorrow’s great companies.

Previous

Dr. Len Schleifer, CEO of Regeneron: Betting on Science and Saving a President